Company news
Carsgen Therapeutics Holdings Ltd. (HKEX:2171) news
Carsgen Therapeutics Holdings Ltd. news releases on 6ix. Latest, Sep 30, 2026: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Press releases & updates
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
September 30, 2026
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES
September 30, 2026
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSE OF CT1190B IN CHINA PHASE I REGISTRATIONAL TRIAL
September 28, 2026
CARsgen Therapeutics Announces 2026 Interim Results
August 17, 2026
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
June 22, 2026
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
June 13, 2026
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
May 30, 2026
CARsgen Therapeutics Announces 2025 Annual Results
March 6, 2026
CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai
February 11, 2026
Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
December 27, 2025
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
December 6, 2025
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
December 7, 2025
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
November 3, 2025
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
October 19, 2025
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
October 19, 2025
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
October 6, 2025
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
September 16, 2025
CARsgen Therapeutics Announces 2025 Interim Results
August 13, 2025
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
July 12, 2025
CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
June 24, 2025
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
May 31, 2025
CARsgen's Satri-cel Granted Priority Review by the NMPA
May 28, 2025
CARsgen's Satri-cel Abstract Available on ASCO Website
May 21, 2025
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
May 10, 2025
CARsgen Announced 2024 Annual Results
March 17, 2025
CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
March 1, 2025
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
February 26, 2025
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
February 25, 2025